Journal of Steroid Biochemistry & Molecular Biology 146 (2015) 74–79

Contents lists available at ScienceDirect

Journal of Steroid Biochemistry and Molecular Biology

journal homepage: www.elsevier.com/locate/jsbmb

Original Research Article

# Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma

Donatella Caruso[a], Federico Abbiati[a], Silvia Giatti[a], Simone Romano[a], Letizia Fusco[b,c], Guido Cavaletti[b,c], Roberto Cosimo Melcangi[a,*]

[a] Department of Pharmacological and Biomolecular Sciences – Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy
[b] Department of Surgery and Translational Medicine, University of Milan-Bicocca, Monza, Italy
[c] Department of Neurology, S. Gerardo Hospital, Monza, Italy

ARTICLE INFO

*Article history:*
Received 27 January 2014
Received in revised form 28 March 2014
Accepted 31 March 2014
Available online 6 April 2014

*Keywords:*
Progesterone
Testosterone
Metabolites
5α-Reductase
Depression
Liquid chromatography–tandem mass spectrometry

ABSTRACT

Observations performed in a subset of patients treated for male pattern hair loss indicate that persistent sexual side effects as well as anxious/depressive symptomatology have been reported even after discontinuation of finasteride treatment. Due to the capability of finasteride to block the metabolism of progesterone (PROG) and/or testosterone (T) we have evaluated, by liquid chromatography–tandem mass spectrometry, the levels of several neuroactive steroids in paired plasma and cerebrospinal fluid (CSF) samples obtained from post-finasteride patients and in healthy controls. At the examination, post-finasteride patients reported muscular stiffness, cramps, tremors and chronic fatigue in the absence of clinical evidence of any muscular disorder or strength reduction. Although severity of the anxious/depressive symptoms was quite variable in their frequency, overall all the subjects had a fairly complex and constant neuropsychiatric pattern. Assessment of neuroactive steroid levels in CSF showed a decrease of PROG and its metabolites, dihydroprogesterone (DHP) and tetrahydroprogesterone (THP), associated with an increase of its precursor pregnenolone (PREG). Altered levels were also observed for T and its metabolites. Thus, a significant decrease of dihydrotestosterone (DHT) associated with an increase of T as well as of 3α-diol was detected. Changes in neuroactive steroid levels also occurred in plasma. An increase of PREG, T, 3α-diol, 3β-diol and 17β-estradiol was associated with decreased levels of DHP and THP. The present observations show that altered levels of neuroactive steroids, associated with depression symptoms, are present in androgenic alopecia patients even after discontinuation of the finasteride treatment.

This article is part of a Special Issue entitled 'Sex steroids and brain disorders'.



## 1. Introduction

Observations obtained in multiple double-blind randomized controlled trials for male pattern hair loss have indicated that finasteride (i.e., a 5α-reductase inhibitor used for the treatment of human benign prostatic hyperplasia and androgenic alopecia) treatment was associated with sexual dysfunction [1–3]. Similar side effects were also reported in patients treated for benign prostatic hyperplasia [4–7]. Very important, observations performed in a subset of patients for male pattern hair loss seem to indicate that persistent sexual side effects (e.g., low libido, erectile dysfunction, decreased arousal and difficulty in reaching orgasm) have been reported even after discontinuation of the treatment [8,9]. Patients also developed depression during finasteride treatment [10,11] that still persisted despite treatment withdrawal [12]. Depression after finasteride treatment might be due to impairment in the levels of neuroactive steroids. This steroid family, which includes both steroid hormones produced in peripheral glands and steroids

*Abbreviations:* 3α-diol, 5α-androstane-3α,17β-diol; 3β-diol, 5α-androstane-3β,17β-diol; 17β-E, 17β-estradiol; AR, androgen receptor; CSF, cerebrospinal fluid; DHEA, dehydroepiandrosterone; DHP, dihydroprogesterone; DHT, dihydrotestosterone; IS, internal standards; LC-MS/MS, liquid chromatography tandem mass spectrometry; PREG, pregnenolone; PROG, progesterone; T, testosterone; THP, tetrahydroprogesterone.

* Corresponding author. Tel.: +39 02 50318238; fax: +39 02 50318204.
*E-mail address:* roberto.melcangi@unimi.it (R.C. Melcangi).

http://dx.doi.org/10.1016/j.jsbmb.2014.03.012
0960-0760/

directly synthesized in the nervous system (i.e., neurosteroids), has an important role in the control of nervous function, affecting mood, behavior, reproduction and cognition, as well as being protective agents in models of injury and neurodegenerative diseases [13–16]. Indeed, finasteride is not only able to block 5α-reductase (5α-R) enzyme, which converts testosterone (T) into dihydrotestosterone (DHT), but also the conversion of progesterone (PROG) into dihydroprogesterone (DHP) [16]. In this context, it is also important to highlight that these neuroactive steroids are then converted by the action of the 3α- or 3β-hydroxysteroid dehydrogenase into 5α-androstane-3α,17β-diol (3α-diol) or 5α-androstane-3β,17β diol (3β-diol) in case of DHT and into tetrahydroprogesterone (THP), also known as allopregnanolone, or into isopregnanolone in case of DHP [16]. It is interesting to note that THP, as well as the 3α-diol (i.e., a metabolite of DHT), are known as ligands of GABA-A receptor [17]. Moreover, isopregnanolone does not bind directly to the GABA-A receptor [18], but it antagonizes the effect of THP on the GABA-A receptor [19,20]. Changes in GABA as well as in neuroactive steroid levels in plasma and cerebrospinal fluid (CSF) are associated with depression in several human studies [21].

Interestingly, our recent preliminary observations obtained in three male patients who received finasteride for the treatment of androgenic alopecia and that after drug discontinuation still had long-term sexual side effects as well as anxious/depressive symptomatology showed altered neuroactive steroid levels in plasma and CSF vs. those assessed in 5 healthy patients [22]. A further link with neuroactive steroids may be supported by recent observations. Indeed, as reported in a subset of post-finasteride patients with persistent symptomatology, a decline in their alcohol consumption was also observed [23]. This is very interesting, because a relationship between GABAergic neuroactive steroids and ethanol consumption is well documented [24].

On the basis of this interesting finding, we here extend our observations analyzing by liquid chromatography–tandem mass spectrometry (LC–MS/MS) the levels of neuroactive steroids, such as pregnenolone (PREG), PROG and its derivatives, DHP, THP and isopregnanolone, dehydroepiandrosterone (DHEA), testosterone (T) and its derivatives, DHT, 3α-diol, 3β-diol and 17β-estradiol (17β-E), in paired plasma and CSF samples obtained from seven post-finasteride patients (i.e., patients who received the drug for the treatment of androgenic alopecia and resulting in long-term sexual side effects as well as anxious/depressive symptomatology after finasteride discontinuation) and comparing these levels vs. those assessed in twelve healthy controls.

## 2. Materials and methods

PREG, PROG, DHP, THP, isopregnanolone, T, DHT, 3α-diol, 3β-diol DHEA and 17β-E were purchased from Sigma Aldrich. 17,21,21,21-$D_4$-PREG ($D_4$-PREG) was kindly synthesized by Dr. P. Ferraboschi (Dept. of Med. Biotech. & Translational Medicine, University of Milano, Italy); 2,2,4,6,6-17α,21,21,21-$D_9$-PROG ($D_9$-PROG) was obtained from Medical Isotopes (Pelham, NH, USA); 2,3,4-$^{13}C_3$-17β-estradiol ($^{13}C_3$-17β-E) was obtained from Sigma-Aldrich, Italy. SPE cartridges (Discovery DS-C18 500 mg) were from Supelco, Italy. All solvents and reagents were HPLC grade (Sigma Aldrich, Italy).

### 2.1. Study design and sample preparation

Patients were recruited through the "Italian network finasteride side effects", where the possibility to undergo CSF and plasma examination in the context of an approved pilot study was made available. Given the exploratory nature of the study no exclusion criteria were established, except the use of drugs known to potentially interfere with neuroactive steroids levels. Symptoms reported by the patients were collected using a standardized questionnaire prepared after consensus among the members of the "Italian network on finasteride side effects" based on an extensive collection of the reported symptoms. The presence of a representative pattern of these symptoms was necessary to be eligible for neuroactive steroid assessment.

The questionnaire was used as a method to systematically collect information on patients conditions and not as a validated tool to assess the features of post-finasteride syndrome. In order to limit selection and recall bias it was filled in by patients only once before they were made aware of the possibility to undergo neuroactive steroid assessment.

The study procedure was approved by the Ethics Committee of the S. Gerardo Hospital, Monza-Italy and the participating subjects provided their written informed consent before enrollment.

In order to obtain reliable normal control values, CSF and plasma were collected from 12 subjects who underwent spinal anesthesia for orthopedic surgery at San Gerardo Hospital of Monza. These subjects were otherwise healthy, were carefully screened for the absence of any neurological or psychiatric disorder in their personal or family history and gave their written informed consent to the use for scientific purpose of the aliquot (approx 100–200 μl) of CFS drawn to verify the correct position of the spinal needle, according to the procedure approved by the Ethics Committee of the S. Gerardo Hospital in Monza.

### 2.2. Quantitative analysis of neuroactive steroids by LC–MS/MS

Extraction and purification of the samples were performed according to Caruso et al. [25].

Briefly, samples were spiked with $^{13}C_3$-17β-E (1 ng/sample), $D_9$-PROG (0.2 ng/sample) and $D_4$-PREG (5 ng/sample), as internal standards (IS) and homogenized in MeOH/acetic acid (99:1 v/v) using a tissue lyser (Qiagen, Italy). After an overnight extraction at 4 °C, samples were centrifuged at 12,000 rpm for 5 min and the pellet was extracted twice with 1 ml of MeOH/acetic acid (99:1, v/v). The organic residues were resuspended with 3 ml of MeOH/$H_2O$ (10:90, v/v) and passed through SPE cartridges, the steroids were eluted in MeOH, concentrated and transferred in autosampler vials before the LC-MS/MS analysis.

### 2.3. Calibration curves

Quantitative analysis was performed on the basis of calibration curves daily prepared and analyzed as previously described [25]. Linear least-square regression analysis was performed and in addition, a blank (non-spiked sample) and a zero sample (only spiked with IS) were run to demonstrate the absence of interferences at the retention times and m/z corresponding to all the analytes. Moreover, the precision of the assay, inter-assay accuracy, precision and reproducibility are calculated as described in [25] and are within tolerance range for all the neuroactive steroids.

### 2.4. Instrumental conditions

Positive atmospheric pressure chemical ionization (APCI+) experiments were performed with a linear ion trap – mass spectrometer (LTQ, ThermoElectron Co, San Jose, CA, USA) using nitrogen as sheath, auxiliary and sweep gas. The instrument was equipped with a Surveyor liquid chromatography (LC) Pump Plus and a Surveyor Autosampler Plus (ThermoElectron Co, San Jose, CA, USA). The mass spectrometer (MS) was employed in tandem mode (MS/MS) using helium as collision gas.

The LC mobile phases were described by Caruso et al. [25]. The Hypersil Gold column (100 mm × 3 mm, 3 μm; ThermoElectron Co.,